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Background-—Lifestyle modification is a key component of cardiovascular disease prevention before and concurrently with
pharmacologic interventions. We evaluated whether lifestyle factors change in relation to the initiation of antihypertensive or lipid-
lowering medication (statins).
Methods and Results-—The study population comprised 41 225 participants of the FPS (Finnish Public Sector) study aged
≥40 years who were free of cardiovascular disease at baseline and responded to ≥2 consecutive surveys administered in 4-year
intervals in 2000–2013. Medication use was ascertained through pharmacy-claims data. Using a series of pre–post data sets, we
compared changes in body mass index, physical activity, alcohol consumption, and smoking between 8837 initiators and 46 021
noninitiators of antihypertensive medications or statins. In participants who initiated medication use, body mass index increased
more (difference in change 0.19; 95% CI, 0.16–0.22) and physical activity declined (0.09 metabolic equivalent of task hour/day;
95% CI, 0.16 to 0.02) compared with noninitiators. The likelihood of becoming obese (odds ratio: 1.82; 95% CI, 1.63–2.03) and
physically inactive (odds ratio: 1.08; 95% CI, 1.01–1.17) was higher in initiators. However, medication initiation was associated
with greater decline in average alcohol consumption (1.85 g/week; 95% CI, 3.67 to 0.14) and higher odds of quitting
smoking (odds ratio for current smoking in the second survey: 0.74; 95% CI, 0.64–0.85).
Conclusions-—These findings suggest that initiation of antihypertensive and statin medication is associated with lifestyle changes,
some favorable and others unfavorable. Weight management and physical activity should be encouraged in individuals prescribed
these medications. ( J Am Heart Assoc. 2020;9:e014168. DOI: 10.1161/JAHA.119.014168.)
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U se of antihypertensive medications and statins for theprimary prevention of cardiovascular disease (CVD) has
expanded over the past few decades1–3 and may increase
further in response to recent guideline changes.4–6 However,
lifestyle modification remains a key component of CVD
prevention before and concurrently with pharmacologic
interventions.4,5,7,8
Whether and how initiation of preventive medication
affects lifestyle remains unclear. Because lifestyle counseling
should precede prescription of preventive medication,8 med-
ication users may have better perception of their CVD risk9,10
and a healthier lifestyle compared with nonusers.11,12 The
perceived effectiveness of pharmacotherapy may provide an
incentive to adhere to a lifestyle that also prevents other
diseases.13,14 The counterargument is that individuals may
substitute medication for a healthy lifestyle and continue an
unhealthy lifestyle or even engage in it,14 which may reduce
the effectiveness of pharmacotherapy.15,16
The diagnosis of CVD or diabetes mellitus has been found
to trigger lifestyle changes, including weight loss,17 increase
in physical activity,18 decrease in alcohol consumption,18 and
smoking cessation.17,19 Participants of the Danish Inter99
trial with hypertension or hyperlipidemia who initiated med-
ication for these conditions were more likely to engage in
favorable dietary changes compared with noninitiators during
5-year follow-up.20 Statin initiators also increased their
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physical activity. Recently, however, studies have reported
lower physical activity among people who initiate21 or use
statins14,22 or antihypertensive medications10 compared with
nonusers. According to the US NHANES (National Health and
Nutrition Examination Survey) data,23 in the early 2000s
statin users had lower caloric and fat intake compared with
nonusers. The difference disappeared by the mid-2000s and
was reversed by 2010. Most recent findings suggested statin
users consumed more calories and fat than nonusers.
Simultaneously, the prevalence of obesity increased faster
among users.22,23
We used repeat observational data to assess the extent to
which initiation of antihypertensive or lipid-lowering (statin)
therapy predicts changes in lifestyle factors, such as body
mass index (BMI), leisure-time physical activity, alcohol
consumption, and smoking, in a large cohort of Finnish
adults. We sought to determine whether initiation of preven-
tive medication is more likely to complement a healthy
lifestyle change or substitute for it. To obtain robust
estimates, we analyzed data as a series of pre–post
studies.24,25
Methods
Study Population and Design
Participants were drawn from the FPS (Finnish Public Sector)
study cohort of employees of 10 towns and 6 hospital
districts.25,26 Data were sourced from questionnaire surveys
administered to FPS subcohorts in 4-year intervals from 2000
to 2013 (average response rate 70%),25 employer records,
and national health registers. We included participants who
responded to ≥2 consecutive surveys (waves 1 and 2) and
were aged ≥40 years and free of CVD at wave 1. Individual-
level survey data could not be made publicly available, but
information on the data and analyses are available upon
request to the corresponding author.
We constructed a long-form data set using subsets of the
original data and organized them into 3 pre–post sets with
separate baselines (2000–2002, 2004–2005, or 2008–2009)
and corresponding follow-ups (2004–2005, 2008–2009, or
2012–2013, respectively). In all, 41 225 participants
belonged to these data sets: 15 880 to 1 data set, 10 143
to 2 data sets, and 15 202 to 3 data sets.
According to Finnish law, written consent is not required
for register-based and survey research as long as the
participation is voluntary. The FPS study participants were
informed about the aims of the study and the record linkage.
The ethics committees of Helsinki University Hospital and the
Finnish Institute of Occupational Health approved the FPS
study protocol.
Initiator, Prevalent User, and Nonuser Cohorts of
Preventive Medication
We used the participants’ personal identification numbers (a
unique number assigned to each Finnish citizen) to link
participants to the electronic records of the Social Insurance
Institution (SII) of Finland covering the years 1994–2011.
Records of pharmacy claims were used to ascertain medica-
tion use. We identified antihypertensive medications with
Anatomical Therapeutic Chemical (ATC) codes C02 (antihy-
pertensives), C03 (diuretics), C07 (b-blockers), C08 (calcium
channel blockers), C09 (renin–angiotensin system blockers),
and C10AA and C10BA02 (both for statins).
We defined initiators as those who filled ≥1 prescription for
any preventive medication for the first time after their
baseline response date but before their wave 2 response
date. Participant observations with no prescription fills by
wave 2 were defined as noninitiators. We focused on
comparing initiators of either antihypertensive medications
or statins with those who remained noninitiators of both. For
secondary comparisons, we included prevalent users, defined
as those participant observations for which ≥1 prescription
for any preventive medication was filled before or on the
baseline response date.
Lifestyle Factors
Height, weight, physical activity, average weekly alcohol
consumption, and smoking status were assessed using
standard questionnaires. Based on self-reported height and
weight, we calculated BMI (kg/m2) and defined BMI 25 to <30
as overweight and BMI ≥30 as obesity. Physical activity was
assessed using the following questions26: “How much did you
exercise per week on average during the past year?” and
Clinical Perspective
What Is New?
• Few longitudinal studies have examined whether initiation of
preventive medication affects lifestyle, either increasing or
decreasing the likelihood of unhealthy behaviors.
What Are the Clinical Implications?
• Because initiation of antihypertensive or statin therapy
appears to be associated with some negative lifestyle
changes, expansion of pharmacologic interventions toward
populations at low cardiovascular disease risk may not
necessarily lead to expected benefits at the population level.
• Effective measures are needed to support the recom-
mended lifestyle change in relation to the initiation of
pharmacologic interventions for primary prevention.
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“Estimate whether the level of intensity of the exercise
corresponded to walking, vigorous walking, jogging, or
running.” The number of hours per week spent on activity
at each intensity level was multiplied by the average energy
expenditure of each activity, expressed in metabolic equiva-
lent of task (MET) hours. We used the sum of MET hours to
identify active (>4 h/day), moderately active (2–4 h/day),
and inactive participants (<2 h/day).27 Drinking habits were
requested as follows28: “Have you ever consumed at least one
glass of some alcoholic drink?” and “How much do you
consume of the following alcoholic drinks on average (beer
per week; wine or other mild drinks per week; spirits per
month)?” We combined alcohol consumption into 1 measure
of average weekly consumption (grams of pure alcohol). High
alcohol consumption equated to consuming >240 g/week in
men and >160 g/week in women.29 In addition, we consid-
ered answering “yes” to the following question as an indicator
of high consumption: “Have you ‘passed out’ due to drinking
during the past year?” Any other consumption was considered
moderate. Smoking status was assessed with the following
questions30: “Do you smoke or have you previously smoked
regularly, that is daily or nearly daily?” and “Do you still smoke
regularly?” Those responding “yes” to the second question
were categorized as current smokers at each survey wave.
Those who responded “yes” to the first and “no” to the
second questions were categorized as former smokers, and
those who responded “no” to both of the questions were
categorized as never smokers. To depict clustering of lifestyle-
related risks, we calculated the number of lifestyles at the
unhealthiest level (obesity, physical inactivity, high alcohol
consumption, current smoking).31
The outcome measures included changes in continuous
BMI, physical activity, alcohol consumption, and number of
cigarettes smoked per day between the waves and the
presence of obesity, physical inactivity, high alcohol con-
sumption, current smoking, or their clustering (3 or 4
unhealthy lifestyles) at wave 2.
Covariates
Covariates were assessed at baseline. Information on sex, age,
employment, and occupational status (upper grade nonmanual
workers, lower grade nonmanual workers, clerks, or manual
workers) came from employer records. Information on marital
status and, for those who had left the FPS organizations,
employment status came from survey responses. Nationwide
hospital discharge and SII special reimbursement registers
were used to ascertain history of CVD (acute myocardial
infarction, chronic coronary heart disease, chronic heart failure,
and stroke) at baseline and between the waves. Information
on special reimbursements and prescription fills (A10) were
used to ascertain history of diabetes mellitus.
Statistical Analyses
The results from the data sets were pooled. We modeled each
lifestyle factor as a separate outcome with a generalized
estimating equation approach accounting for within-person
correlation across data sets and applied bootstrapping to
obtain stable 95% CIs.
We estimated the associations between medication initi-
ation and continuous outcomes using linear regression.
Associations with unhealthy lifestyles at wave 2 were
estimated with logistic regression, stratifying by presence of
the respective unhealthy lifestyle at baseline. To account for
the changes in clinical guidelines and prescribing and the
general lifestyle trends, all models included baseline period
and time interval between the survey waves, as this interval
influences the potential for change in lifestyles. Fully adjusted
models included age; sex; marital, occupational, and employ-
ment status; diabetes mellitus; and other lifestyle factors
measured at baseline. Participant observations that were
missing data on any covariate were excluded from the
multivariable models.
Sensitivity and Subgroup Analyses
First, we excluded participant observations with diabetes
mellitus at baseline and those diagnosed with diabetes
mellitus or CVD between waves 1 and 2 because our focus
was on primary prevention. Second, to identify true medica-
tion initiators, we redefined initiation as refilling a prescription
for preventive medication at least once within a year since
initiation. Third, to confirm the temporal order between
medication initiation and lifestyle change, we restricted our
cohort to respondents of 3 consecutive surveys and com-
pared the presence of unhealthy lifestyles at wave 3 between
initiators and noninitiators who maintained the same lifestyle
at waves 1 and 2.25 Fourth, we repeated the main analyses
separately for antihypertensive medications and statins to see
whether the results were specific to a therapeutic class. Last,
we stratified the analyses by baseline period and sex. We
tested statistical significance of the interactions by including
user-group-by-period or user-group-by-sex interaction terms in
the outcome models, respectively. Analyses were performed
using SAS v9.4 (SAS Institute).
Results
Of a total of 81 772 participant observations based on the
41 225 FPS participants, 84% were female, with mean age of
527.2 years (Table 1); and 8837 (10.8%) presented as
initiators of preventive medication, 26 914 (32.9%) as preva-
lent users, and 46 021 (56.3%) as noninitiators between
waves 1 and 2 (mean interval: 4.0 years; range: 2.0–
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Table 1. Baseline Characteristics of the 81 772 Participant Observations
Characteristic All Observations (n=81 772) Initiators (n=8837) Prevalent Users (n=26 914) Noninitiators (n=46 021)
Baseline year, %
2000–2002 25.8 27.2 18.3 29.9
2004–2005 33.4 42.0 31.5 32.8
2008–2009 40.8 30.8 50.2 37.4
Age, y, mean (SD) 52.2 (7.24) 52.4 (6.61) 55.1 (7.24) 50.4 (6.78)
40–49 41.7 38.0 25.7 51.7
50–59 43.1 49.0 48.4 38.8
60–78 15.3 13.0 25.9 9.5
Women, % 83.9 83.8 82.6 84.3
Married/cohabiting, % 76.3 76.5 75.6 76.6
Occupational status, %
Upper grade nonmanual workers 32.1 29.8 30.6 33.3
Lower grade nonmanual workers 26.5 26.1 25.4 27.2
Clerks 7.4 7.2 8.3 6.9
Manual workers 34.1 36.9 35.7 32.6
Employed, % 89.4 92.3 81.0 93.7
Body weight, %
Normal 49.8 43.0 37.2 58.3
Overweight 35.5 39.4 39.8 32.3
Obese 14.7 17.6 23.0 9.4
Physical activity, %
Active 40.8 38.1 34.5 45.0
Moderate 33.6 33.5 34.7 33.0
Inactive 25.6 28.4 30.9 22.0
Alcohol consumption, %
Moderate 71.7 70.9 69.5 73.2
None 14.9 14.3 16.5 14.1
High 13.4 14.8 14.1 12.7
Smoking, %
Never 68.2 65.1 68.5 68.6
Former 18.3 19.7 19.5 17.4
Current 13.4 15.1 12.0 14.0
No. of unhealthy lifestyles,* %
0 52.0 47.0 45.4 56.8
1–2 45.2 49.3 50.7 41.3
3–4 2.8 3.6 3.9 2.0
History of antihypertensive medication use, % 29.3 NA 89.1 NA
History of statin use, % 9.6 NA 29.1 NA
Diabetes mellitus, % 2.7 2.0 6.7 0.6
The observations are based on the 41 225 participants of the FPS (Finnish Public Sector) study. Numbers are percentages unless otherwise specified. Of all participant observations
included, 79 889 (97.7%) had data available on body mass index, 80 988 (99.0%) on physical activity, 81 337 (99.5%) on alcohol consumption, and 79 675 (97.4%) on smoking at baseline.
NA indicates not applicable.
*Obesity, physical inactivity, high alcohol consumption, and current smoking.
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5.4 years). Medication initiation took place a median of 1.7
years (interquartile range: 0.9–2.7 years) after baseline and a
median of 2.4 years (interquartile range: 1.3–3.3 years) before
the second survey wave. Between waves, 318 (3.6%) initia-
tors, 477 (1.8%) prevalent users, and 48 (0.1%) noninitiators
were newly diagnosed with CVD.
Change in Lifestyle
Average BMI increased among both initiators and noninitia-
tors (Table 2), but in the fully adjusted model, the mean
increase in BMI was larger (difference in change: 0.19; 95% CI,
0.16–0.22) among initiators. Among wave 1 obese partici-
pants, the odds of obesity at wave 2 were 1.37 times greater
(95% CI, 1.15–1.65) for initiators compared with noninitiators
(Figure). Among wave 1 nonobese participants, the odds of
obesity at wave 2 were 1.82 times greater (95% CI, 1.63–
2.03) for initiators versus noninitiators. Furthermore, average
MET h/day declined among initiators versus noninitiators
(0.09; 95% CI, 0.16 to 0.02; Table 2). Initiators had
greater odds of physical inactivity at wave 2 regardless of
baseline activity (Figure). Table S1 shows the shifts of
participant observations between levels of lifestyle factors
within user groups.
Average weekly alcohol consumption declined more among
initiators compared with noninitiators (1.85 g/week; 95%
CI, 3.67 to 0.14; Table 2). When the comparison was
restricted to those initiators (n=7014) and noninitiators
(n=37 297) who reported any alcohol consumption at both
waves, the adjusted difference in change in weekly consump-
tion was 1.67 g (95% CI, 3.72 to 0.39). No difference in
the odds of high alcohol consumption at wave 2 was observed
between user groups regardless of baseline drinking (Figure).
The prevalence of current smoking tended to decrease in
all subgroups (Table 1, Table S1). However, baseline smokers
who initiated medication use were more likely to quit smoking
compared with smokers who remained untreated (adjusted
odds ratio [OR] for current smoking among initiators versus
noninitiators: 0.74; 95% CI, 0.64–0.85; Figure). Furthermore,
initiators who were current smokers at both waves decreased
Table 2. Changes in BMI, Physical Activity, and Alcohol Consumption Between the Survey Waves in Initiators and Prevalent Users
of Preventive Medication Versus Noninitiators
Lifestyle Factor/User Group
Outcome
Mean (SD*)
Mean Change (P Value*)
b Value (95% CI)†
Baseline Second Survey Unadjusted Difference‡ Adjusted Difference§
BMI, kg/m2
Initiators (n=8425) 26.3 (4.2) 26.8 (4.5) 0.51 (<0.001) 0.13 (0.08–0.17) 0.19 (0.16–0.22)
Prevalent users (n=25 348) 27.0 (4.6) 27.3 (4.7) 0.31 (<0.001) 0.04 (0.07 to 0.01) 0.08 (0.06–0.10)
Noninitiators (n=44 091) 24.9 (3.7) 25.2 (3.9) 0.37 (<0.001) Reference Reference
Physical activity (MET h/d)
Initiators (n=8658) 4.15 (3.77) 3.97 (3.60) 0.18 (<0.001) 0.13 (0.22 to 0.04) 0.09 (0.16 to 0.02)
Prevalent users (n=26 368) 3.78 (3.44) 3.69 (3.38) 0.09 (<0.001) 0.12 (0.17 to 0.06) 0.08 (0.13 to 0.04)
Noninitiators (n=45 312) 4.71 (4.00) 4.70 (4.03) 0.01 (0.47) Reference Reference
Alcohol consumption, g/wk
Initiators (n=8721) 69.0 (108) 66.4 (110) 2.64 (0.011) 2.57 (4.75 to 0.38) 1.85 (3.67 to 0.14)
Prevalent users (n=26 546) 66.7 (109) 63.9 (111) 2.38 (<0.001) 1.73 (3.13 to 0.34) 0.72 (1.92 to 0.49)
Noninitiators (n=45 488) 61.1 (93.2) 60.6 (95.6) 0.44 (0.26) Reference Reference
No. of cigarettes/dayk
Initiators (n=876) 13.1 (7.05) 12.5 (6.83) 0.60 (<0.001) 0.37 (0.63 to 0.11) 0.34 (0.60 to 0.08)
Prevalent users (n=2251) 12.3 (6.65) 12.1 (6.71) 0.23 (0.016) 0.02 (0.20 to 0.16) 0.05 (0.13 to 0.24)
Noninitiators (n=4532) 11.9 (6.60) 11.7 (6.45) 0.19 (0.002) Reference Reference
Only participant-observations who had data available on all baseline covariates were included in adjusted models (n=74 291 or 95.4% of those with data on body mass index at both
surveys, n=75 613 or 94.1% of those with data on physical activity at both surveys, n=75 781 or 93.8% of those with data on alcohol consumption at both surveys, n=7339 or 95.8% of
those reporting number of cigarettes smoked at both surveys). BMI indicates body mass index; MET, metabolic equivalent of task.
*SDs and P values reported here do not take into account that each individual may have contributed to >1 data set.
†Derived from generalized estimating equations.
‡Adjusted for baseline year and time interval between the survey waves.
§Adjusted for baseline year; time interval; age; sex; marital, occupational, and employment status; diabetes mellitus; smoking status; and other lifestyle factors.
kAmong those who were current smokers at both waves.
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smoking more than their noninitiator counterparts (adjusted
difference in change in the number of cigarettes per day:
0.34; 95% CI: 0.60 to 0.08; Table 2).
Among those with 0–2 unhealthy lifestyles at baseline, the
adjusted OR of a cluster of 3 to 4 unhealthy lifestyles at wave
2 was 1.66 (95% CI, 1.40–1.98) for initiators compared with
noninitiators (Figure). The relative difference between user
groups was smaller in the subgroup that already had 3 to 4
unhealthy lifestyles at baseline. In this subgroup (n=1231),
BMI increased (adjusted difference: 0.32; 95% CI, 0.06–0.59)
and MET h/day declined (0.33; 95% CI, 0.57 to 0.09)
more among initiators compared with noninitiators, whereas
there was no significant difference in change in average
alcohol consumption (0.09 g/week; 95% CI, 17.6 to 17.8) or
in the odds of current smoking at wave 2 (adjusted OR: 0.92;
95% CI, 0.69–1.24).
Prevalent users’ lifestyle changed in the same direction as
initiators’ lifestyle, although the average changes in BMI and
weekly alcohol consumption were smaller in comparison with
noninitiators (Table 2). Prevalent users were more likely to
develop obesity, physical inactivity, and high alcohol con-
sumption than were noninitiators (Figure). Within the sub-
group with 0 to 2 unhealthy lifestyles at baseline, in particular,
prevalent users had twice the odds of having 3 to 4 unhealthy
lifestyles at wave 2 compared with noninitiators (adjusted OR:
2.02; 95% CI, 1.78–2.28).
Sensitivity and Subgroup Analyses
Exclusion of participants with diabetes mellitus or new CVD
(Tables S2 and S3) or initiators with no refills within the first
year since initiation (Tables S4 and S5) did not materially
change the main results. The analyses including initiators and
noninitiators who maintained the same lifestyle at waves 1
and 2 showed that initiators were more likely to develop
obesity and a cluster of unhealthy lifestyles by wave 3
(Table S6). These analyses support the temporal order
between medication initiation and unhealthy lifestyle change.
The associations between antihypertensive medication use
and lifestyle changes resembled those in the main analyses
(Tables S7 and S8). Conversely, the associations for statin
initiation were generally weaker. However, statin initiation
appeared to be more strongly associated with decline in
average weekly alcohol consumption (2.38 g; 95% CI,
4.33 to 0.43) and quitting smoking (OR for current
smoking: 0.63; 95% CI, 0.53–0.75). Almost half (43.9%) of
Figure. Adjusted odds ratios (ORs) for unhealthy lifestyles at the second survey for users of preventive medication (vs noninitiators) by
presence of the respective unhealthy lifestyle at baseline. Number of participant observations and prevalence of unhealthy lifestyle at the
second survey in parentheses.
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initiators and 24.3% of noninitiators of statins were users of
antihypertensive medication at wave 1 (Table S9). In addition,
7.6% of initiators of antihypertensive medication and 4.7% of
noninitiators had used statins.
The baseline period did not appear to modify the associ-
ations between user group and changes in BMI, alcohol
consumption, or physical activity or between user group and
odds of any of unhealthy behaviors at wave 2 (Tables S10 and
S11; P>0.05 for user group-by-period interactions). Sex did
not modify the associations between user group and change
in BMI or weekly alcohol consumption or between user group
and odds of any of unhealthy behaviors at wave 2 (Tables S12
and S13; P>0.05 for user-group-by-sex interactions). The
average decline in physical activity was of the same
magnitude in both sexes (Table S12). Among women,
however, physical activity declined more among initiators
than noninitiators (adjusted difference in change: 0.11 MET
h/day; 95% CI, 0.19 to 0.04). Among men, no difference
was found (adjusted difference in change: 0.01 MET h/day;
95% CI, 0.19 to 0.20; P=0.20 for user group-by-sex
interaction). In the subgroup of physically inactive participants
at baseline, the odds of physical inactivity associated with
medication initiation were increased among women (OR: 1.20;
95% CI, 1.08–1.32) but not in men (OR: 1.01; 95% CI, 0.81–
1.26; P=0.21 for user-group-by-sex interaction). Among those
at least moderately active at baseline, no such sex difference
was observed (OR, women: 1.10 [95% CI, 1.00–1.22]; men:
1.09 [95% CI, 0.91–1.30]).
Discussion
In this large cohort study of Finnish adults free of CVD, there
are 4 key findings. First, initiators experienced greater
increases in BMI and were more likely to become obese than
did noninitiators. This attenuates positive treatment effects
and supports the substitution hypothesis. Second, the
likelihood of becoming physically inactive was higher among
initiators, a finding supporting the substitution hypothesis.
Third, in support of the complementation hypothesis, smokers
who initiated preventive medication were more likely to either
quit or decrease smoking compared with untreated smokers.
This is likely to amplify the effectiveness of pharmacotherapy.
Fourth, although average alcohol consumption decreased
more among initiators than noninitiators, there was no
difference in the odds of heavy drinking.
This was the first large-scale, prospective, cohort study
on the associations between use of preventive medications
and lifestyle change. Prior research on the relationships
between preventive medication use and lifestyle has
typically considered either use of antihypertensive medica-
tions10,32 or statins9,11,14,21–23,33 but rarely both.12,20 Most
previous studies have been cross-sectional9,11,14,22,23,33 and
provide no information on potential lifestyle changes during
the time window around the initiation of medication use. We
included both antihypertensive and statin medications and
also studied them separately. Using individual-level data
with repeated measurements, we were able to determine
each individual’s lifestyle before and after medication
initiation.
Our results on greater declines in smoking and increases in
obesity among initiators of preventive medication agree with
those from a small Canadian cohort study involving 769 new
hypertensive participants of the National Population Survey
(1994–2002) who also reported use of antihypertensive
medication.32 Another longitudinal study based on the
Framingham Heart Study Offspring Cohort (1983–2001)
showed an increase in obesity among statin users but no
clear decrease in smoking.14 Furthermore, statin use was
associated with an increase in moderate alcohol consumption
and physical activity in men but not in women. In addition, a
study including 871 participants of the Inter99 health
behavior intervention trial reported an association between
increased physical activity and likelihood of initiating statin
use over a 5-year period (up to 2006),20 but no association
was observed with initiation of antihypertensive medication.
These results are consistent with the observations in our
study population, the majority of whom started preventive
therapy with antihypertensive medications. Together with the
preceding observations and data from repeated cross-
sectional surveys from the United States23 and Korea22
showing faster increases in fat and caloric intake, obesity, and
physical inactivity among statin users versus nonusers, our
study provides more support for the substitution hypothesis
(unfavorable or no lifestyle change) than for the complemen-
tation hypothesis (positive lifestyle change).
Statin initiation is associated with increase in muscle
complaints,34 potentially interfering with physical activity. A
US study among older men reported that prevalent statin use
was associated with modestly lower physical activity.21
However, a longitudinal analysis showed that physical activity
declined faster among initiators than among prevalent users
or noninitiators. We observed virtually no differences in
change in physical activity between initiators, prevalent users,
and nonusers of statins in our cohort, which was younger,
predominantly female, and free of CVD.
It is well documented that smoking cessation often results
in weight gain, particularly in women, that cannot be
prevented by increasing physical activity.35 In our data, the
average increase in BMI among quitters was 1.20 (SD: 2.05)
for initiators and 1.09 (SD: 2.07) for noninitiators (data not
shown). Although initiation of preventive medication was
associated with quitting smoking, the difference in the
increase of BMI remained approximately the same for
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initiators and noninitiators after excluding the quitters
(adjusted difference: 0.18; 95% CI, 0.15–0.22).
Limitations
A key limitation of our study is the generalizability of the results.
Our study population consisted of a relatively homogenous
sample of white public sector workers, with only 16% of the
participant observations related to men and the mean age being
slightly >50 years. Furthermore, during the study period,
intensive public health action took place in Finland36 and may
have affected the lifestyles of both medication users and
nonusers. For example, smoking in public indoor places and
workplaces was prohibited already in the 1990s and in
restaurants in 2006. The national development program for
the prevention and care of diabetes mellitus was implemented
in 2000–2010.37 This program aimed to increase awareness of
diabetes mellitus and its risk factors (including the same
lifestyle factors considered in this study) in the whole population
through various activities, such as media campaigns and health
fairs. Consequently, our results may not be generalizable to
countries or settings with different preventive policies.
Furthermore, initiators of preventive medication have
presumably received counseling from health professionals
before initiation, as the clinical guidelines have recommended
lifestyle change lasting for weeks or months as the sole
intervention among individuals in primary prevention.29,38
Unfortunately, we have no information on the contents and
timing of this counseling or other forms of health promotion
to which the medication users in this study were exposed.
Because some participants may have initiated lifestyle change
before baseline, we may have underestimated the change
related to medication initiation. However, high-risk behaviors
were more common among initiators than noninitiators at
baseline; therefore, there was more room for improvement.
We did not have information on each participant’s diet (eg,
fat or fruit and vegetable intake), blood pressure, or cholesterol
levels. Our noninitiator population is likely to be a mixture of
patients free of hypertension or dyslipidemia and those who
may have been diagnosed with these conditions but did not use
medications; that is, a small proportion of noninitiators may be
individuals among whom lifestyle modification alone was
effective. Our definition of medication use was based on
dispensation data, and we could not verify whether and how the
dispensed medications were consumed. Self-reporting has
been found to underestimate obesity,39 smoking,40 and alcohol
consumption.41 However, this is unlikely to have changed
between waves, and each lifestyle factor has been shown to be
associated with increased all-cause mortality and CVD event
risk in these data, except for high alcohol consumption.26
In sensitivity analyses, we excluded participant observa-
tions linked to records indicating myocardial infarction,
chronic coronary heart disease, chronic heart failure, or
stroke between the survey waves and those indicating
diabetes mellitus at any time before the second wave. This
did not alter observed associations. However, other condi-
tions such as respiratory events, cancers, or chronic
gastrointestinal disease could also affect lifestyle factors
and, if distributed unevenly between initiators and noninitia-
tors of preventive medication, may have confounded the
associations between medication initiation and lifestyle
change. Furthermore, it is possible that the associations
between medication initiation and increases in BMI were
confounded by menopausal status (among women) or age-
related weight gain. When we analyzed these associations
within 10-year age groups, BMI seemed to increase more
among initiators than noninitiators in each age group, but the
association between medication initiation and change in BMI
was stronger among those aged 40 to 49 years (adjusted
difference in change in BMI: 0.30; 95% CI, 0.22–0.37) than
among the older age groups in the whole study population
(adjusted difference in change in BMI, 50–59 years: 0.11
[95% CI, 0.05–0.17]; ≥60 years: 0.13 [95% CI, 0.02–0.24).
This was true for women and men (data not shown); therefore,
our conclusions did not change.
Our findings support the notion that there is scope to
improve management of lifestyle-related risk factors among
individuals who have initiated preventive medication. Patients’
awareness of their risk factors alone seems not to be effective
in improving health behaviors.42 The most recent primary
prevention guidelines in Europe8 and the United States43
emphasize cognitive-behavioral strategies (eg, motivational
interviewing, shared decision-making), multidisciplinary and
team-based approaches, and evaluation of social and other
individual-level determinants of health when choosing the
optimal strategy for each patient.
Perspectives
Initiation of antihypertensive or statin therapy appears to be
associated with lifestyle changes, some positive and others
negative. This means that expansion of pharmacologic
interventions toward populations at low CVD risk may not
necessarily lead to expected benefits at the population level.
More effective measures are needed to support the recom-
mended lifestyle change in relation to the initiation of
pharmacologic interventions for primary prevention.
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Table S1. Cross-tabulation of unhealthy lifestyle factors at baseline and during 
the second survey wave by use of preventive medication. 
Second survey (wave 2) 
Initiators Prevalent user Non-initiators 
Baseline Yes No Yes No Yes No 
(wave 1) No. (%) No. (%) No. (%) No. (%) No. (%) No. (%) 
Obesity 
Yes 1252 (86.2) 200 (13.8) 4935 (86.1) 792 (13.8) 3326 (82.4) 712 (17.6) 
No 503 (7.2) 6470 (92.8) 1365 (7.0) 18 256 (93.0) 1574 (3.9) 38 479 (96.1) 
Total 1755 (20.8) 6670 (79.2) 6300 (24.9) 19 048 (75.2) 4900 (11.1) 39 191 (88.9) 
P value
*
<.001 <.001 <.001 
Physical inactivity 
Yes 1355 (55.4) 1093 (44.7) 4715(58.2) 3390 (41.8)   4929 (49.6) 5001 (50.4) 
No 1193 (19.2) 5017 (80.8) 3853 (21.1) 14 410 (78.9)   5334 (15.1) 30 048 (84.9) 
Total 2548 (29.4)  6110 (70.6) 8568 (32.5) 17 800 (67.5)  10 263 (22.7) 35 049 (77.4) 
P value
*
.04 <.001 . <.001 
High alcohol consumption 
Yes 769 (59.2) 527 (40.7) 2180 (58.3) 1557 (41.7) 3375 (58.4) 2406 (41.6) 
No 460 (6.20) 6965 (93.8) 1390 (6.09) 21 420 (93.9) 2354 (5.93) 37 355 (94.1) 
Total 1229 (14.1) 7492 (85.9) 3570 (13.5) 22 977 (86.6) 5729 (12.6) 39 761 (87.4) 
P value
*
.03 .002 ..45 
Current smoking 
Yes 887 (71.7) 351 (28.4) 2263 (75.7) 725 (24.3) 4575 (77.7) 1317 (22.4) 
No 121 (1.7) 7076 (98.3) 353 (1.54) 22 449 (99.5) 636 (1.67) 37 501 (98.3) 
Total 1008 (12.0) 7427 (88.1) 2616 (10.1) 23 224 (89.9) 5211 (11.8) 38 818 (88.2) 
P value
*
<.001 <.001 <.001 
Cluster of 3–4 unhealthy lifestyles 
Yes 145 (45.2) 176 (54.8) 486 (46.6) 556 (53.4) 359 (39.5) 551 (60.6) 
No 186 (2.2) 8288 (97.8) 604 (2.4) 25 126 (97.7) 601 (1.3) 44 387 (98.7) 
Total 331 (3.8) 8464 (96.2) 1090 (4.1) 25 682 (95.9) 960 (2.1) 44 938 (97.9) 
P value
*
.53 .16 .14 
Total number of participant-observations (% of those with data at baseline) who had data available on 
body mass index at both surveys 77 864 (97.5%), on physical activity 80 338 (99.2%), on alcohol 
consumption 80 758 (99.4%), and on smoking 78 304 (98.3%).  
*
P values for test of pre-post change derived from McNemar’s test. P values reported here do not take
into account that each participant may have contributed to more than one dataset.
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Table S2. Changes in body mass index, physical activity and alcohol 
consumption from the baseline survey to the second survey wave among users 
of preventive medication versus non-initiators. Those with cardiovascular 
disease or diabetes prior to the second survey excluded.  
Outcome 
Lifestyle 
factor/ 
Mean (SD
*
) Mean 
change 
β value (95% CI) 
User group Baseline 2
nd
 survey (P value
*
) Unadjusted
difference
†
Adjusted difference
‡
Body mass index (kg/m2) 
Initiators 
(n=7645) 
26.1 (4.02) 26.6 (4.30) 0.55 
(<.001) 
0.16 (0.13–0.20) 0.21 (0.18–0.24) 
Prevalent  users 
(n=22 380) 
26.6 (4.33) 27.0 (4.52) 0.36 
(<.001) 
-0.01 (-0.03–0.01) 0.10 (0.08–0.12) 
Non-initiators 
(n=43 616) 
24.8 (3.66) 25.2 (3.84) 0.38 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=7851) 
4.15 (3.72) 4.00 (3.60) -0.14
(<.001)
-0.10 (-0.18–0.03) -0.09 (-0.15-[-0.02])
Prevalent users 
(n=23 229) 
3.89 (3.48) 3.79 (2.89) -0.10
(<.001)
-0.12 (-0.17–[-0.08]) -0.09 (-0.14–[-0.04])
Non-initiators 
(n=44 809) 
4.70 (4.01) 4.69 (4.03) -0.01
(.54)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=7907) 
68.2 (107) 65.8 (109) -2.41
(.02)
-2.35 (-4.09–[-0.62]) -2.00 (-3.76–[-0.23])
Prevalent users 
(n=23 386) 
65.4 (106) 63.2 (108) -2.23
(<.001)
-1.67 (-2.83–[-0.52]) -0.86 (-2.08–0.37)
Non-initiators 
(n=44 986)   
61.0 (93.0) 60.6 (95.6) -0.38
(0.32)
Reference Reference 
Number of cigarettes /day
¶
Initiators 
(n=763) 
12.7 (6.70) 12.2 (6.66) -0.46
(0.003)
-0.28 (-0.54-[-0.02]) -0.23 (-0.49-0.03)
Prevalent users 
(n=1938) 
12.0 (6.61) 11.8 (6.47) -0.21
(0.03)
0.0002 (-0.18-0.18) 0.09 (-0.09-0.28) 
Non-initiators 
(n=4468)   
11.9 (6.57) 11.7 (6.44) -0.20
(0.002)
Reference Reference 
CI=confidence interval, MET=metabolic equivalent of task, SD=standard deviation. 
*
SDs and P values reported here do not take into account that each participant may have contributed to 
more than one dataset. 
†
adjusted for baseline year and time interval between the survey waves. 
‡
adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, 
smoking status and other lifestyle factors at baseline. 
¶ 
among those who were current smokers at both waves. 
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Table S3. Odds ratios for obesity, physical inactivity, high alcohol 
consumption, and current smoking at the second survey wave for users of 
preventive medication (versus non-initiators) stratified by presence of the 
respective unhealthy lifestyle at baseline. Those with cardiovascular disease or 
diabetes prior to the second survey excluded. 
Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
*
Adjusted
† Unadjusted
*
Adjusted
†
(wave 1) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Ref. 
Obesity 
Yes 1.47 (1.20–1.80) 1.50 (1.22–1.83) 1.29 (1.14–1.46) 1.35 (1.18–1.55) 1.00 
No  1.82 (1.64–2.03) 1.82 (1.63–2.02) 1.69 (1.56–1.83) 1.79 (1.64–1.95) 1.00 
Physical inactivity 
Yes 1.23 (1.121.37) 1.13 (1.02–1.26) 1.34 (1.26–1.42) 1.20 (1.12–1.29) 1.00 
No  1.22 (1.13–1.32) 1.07 (0.99–1.16) 1.42 (1.36–1.49) 1.18 (1.13–1.24) 1.00. 
High alcohol consumption 
Yes  1.05 (0.92–1.20) 1.07 (0.93–1.22) 1.03 (0.94–1.13) 1.05 (0.95–1.15) 1.00 
No  1.03 (0.92–1.16) 1.08 (0.96–1.21) 1.03 (0.96–1.11) 1.18 (1.09–1.28) 1.00 
Current smoking 
Yes 0.77 (0.66–0.89) 0.76 (0.65–0.90) 0.98 (0.87–1.10) 0.97 (0.86–1.09) 1.00 
No 0.98 (0.79–1.22) 1.00 (0.80–1.25) 0.93 (0.81–1.08) 1.11 (0.95–1.30) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes  1.27 (0.95–1.70) 1.31 (0.98–1.75) 1.22 (1.00–1.48) 1.32 (1.07–1.62) 1.00 
No 1.57 (1.30–1.90) 1.67 (1.38–2.03) 1.64 (1.44–1.87) 1.95 (1.71-2.23) 1.00 
CI=confidence interval, OR=odds ratio. 
*
adjusted for baseline year and time interval between the survey waves.
†
adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, and 
other lifestyle factors at baseline (except for the cluster variable). 
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Table S4. Changes in body mass index, physical activity, and alcohol 
consumption from the baseline survey to the second survey wave among 
initiators with at least 1 refill of preventive medication versus non-initiators.  
Outcome 
Lifestyle 
factor/ 
Mean (SD
*
) Mean 
change 
β value (95% CI) 
Unadjusted Adjusted 
User group Baseline 2
nd
 survey (P value
*
) differencec
† difference
‡
Body mass index (kg/m2) 
Initiators with 1+ refills during the first year 
(n=6729) 26.5 (4.21) 27.0 (4.47) 0.53 (<.001) 0.13 (0.10–0.17) 0.20 (0.16–0.24) 
Initiators with 2+ refills during the first year
§
(n=5934) 26.6 (4.23) 27.1 (4.49) 0.53 (<.001) 0.13 (0.09-0.17) 0.20 (0.16-0.24) 
Non-initiators 
(n=44 091) 
24.9 (3.69) 25.2 (3.86) 0.37 (<.001) Reference Reference 
Physical activity (MET-hours/day) 
Initiators with 1+ refills during the first year 
(n=6923) 4.07 (3.73) 3.89 (3.55) -0.18 (<.001) -0.12 (-0.20–[-0.05]) -0.09 (-0.17–[-0.01])
Initiators with 2+ refills during the first year
§
(n=6106) 4.03 (3.69) 3.85 (3.48) -0.19 (<.001) -0.12 (-0.19–[-0.04]) -0.08 (-0.16–[-0.002])
Non-initiators 
(n=45 312) 
4.69 (4.01) 4.68 (4.03) -0.01 (.47) Reference Reference
Alcohol consumption (grams/week) 
Initiators with 1+ refills during the first year 
(n=6975) 70.9 (113) 68.0 (114) -2.89 (.01) -2.42 (-4.14–[-0.70]) -1.93 (-3.74–[-0.12])
Initiators with 2+ refills during the first year
§
(n=6149) 71.4 (112) 68.2 (116) -3.17 (.01) -3.13 (-5.20–[-1.06]) -2.27 (-4.41–[-0.14])
Non-initiators 
(n=45 488)   
61.1 (93.2) 60.6 (95.6) -0.44 (.26) Reference Reference
CI=confidence interval, MET=metabolic equivalent of task, SD=standard deviation. 
*
SDs and P values reported here do not take into account that each participant may have contributed to 
more than one dataset.  
†
adjusted for baseline year and time interval between the survey waves.
‡
adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, 
smoking status and other lifestyle factors at baseline.  
§
According to the Finnish reimbursement rules, medications can be reimbursed for a maximum of 3 
month-period at one transaction. Initial fill and 2 refills with a 3-month supply each would lead to 80+% 
adherence level during the first year. 
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Table S5. Odds ratios for obesity, physical inactivity, high alcohol consumption, 
and current smoking at the second survey wave for initiators of preventive 
medication with at least 1 refill (versus non-initiators) stratified by presence of 
the respective unhealthy lifestyle at baseline.  
Initiators 
Baseline 1+ refills during the first year 2+ refills during the first year 
‡
(wave 1) Unadjusted* 
OR (95% CI) 
Adjusted
†
 
OR (95% CI) 
Unadjusted* 
OR (95% CI) 
Adjusted
†
OR (95% CI) 
Obesity 
Yes 1.43 (1.17–1.73) 1.46 (1.20–1.79) 1.39 (1.13–1.70) 1.42 (1.16–1.75) 
No  1.93 (1.72–2.16) 1.93 (1.72–2.16) 1.96 (1.72–2.23) 1.95 (1.71–2.22) 
  Physical inactivity 
Yes 1.30 (1.17–1.43) 1.15 (1.03–1.27) 1.33 (1.20–1.47) 1.17 (1.05–1.30) 
No  1.34 (1.23–1.45) 1.10 (1.02–1.20) 1.37 (1.25–1.48) 1.11 (1.02–1.21) 
High alcohol consumption 
Yes  1.01 (0.88–1.15) 1.00 (0.86–1.14) 0.99 (0.86–1.14) 0.98 (0.84–1.13) 
No  1.07 (0.95–1.21) 1.12 (0.98–1.27) 1.04 (0.93–1.18) 1.09 (0.96–1.23) 
Current smoking 
Yes 0.73 (0.62–0.85) 0.72 (0.61–0.84) 0.72 (0.61–0.86) 0.71 (0.60–0.86) 
No 0.96 (0.77–1.21) 0.98 (0.79–1.23) 1.01 (0.80–1.27) 1.02 (0.81–1.30) 
Cluster of 3–4 unhealthy lifestyles 
Yes  1.42 (1.08–1.86) 1.46 (1.11–1.92) 1.31 (1.00–1.72) 1.34 (1.01–1.78) 
No 1.68 (1.41–2.01) 1.75 (1.45–2.10) 1.71 (1.42–-2.06) 1.78 (1.46–2.16) 
CI=confidence interval, OR=odds ratio. 
*
adjusted for baseline year and time interval between the survey waves.
†
adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, and 
other lifestyle factors at baseline (except for the cluster variable). 
‡
According to the Finnish reimbursement rules, medications can be reimbursed for a maximum of 3 
month-period at one transaction. Initial fill and 2 refills with a 3-month supply each would lead to 80+% 
adherence level during the first year. 
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Table S6. Odds ratios for obesity, physical inactivity, high alcohol 
consumption, and current smoking at the third survey wave for initiators of 
preventive medication (versus non-initiators) stratified by presence/absence of 
the respective unhealthy lifestyle at baseline and wave 2. 
Both at waves 1 and 2 Unadjusted
*
 OR (95% CI) Adjusted
†
 OR (95% CI)
Obesity 
Yes (n=2213; 1995 cases ) 1.23 (0.90–1.69) 1.22 (0.86–1.75) 
No (n=23 986; 963 cases) 1.71 (1.46–2.01) 1.77 (1.50–2.10) 
Physical inactivity 
Yes (n=3269, 428 cases) 1.24 (1.03–1.50) 1.07 (0.87–1.30) 
No (n=18 880,  2291 cases) 1.25 (1.12–1.40) 1.12 (0.99–1.25) 
High alcohol consumption 
Yes (n=2240, 1559 cases) 1.04 (0.83–1.31) 1.04 (0.81–1.33) 
No (n=23 735, 1008 cases) 1.04 (0.87–1.23) 1.05 (0.87–1.27) 
Current smoking 
Yes (n=2825; 2184 cases) 1.04 (0.82–1.31) 1.02 (0.80-1.31) 
No (n=23 734; 186 cases) 0.99 (0.80–1.21) 1.06 (0.70–1.61) 
Cluster of 3–4 unhealthy lifestyles 
Yes (n=273, 134 cases) 0.76 (0.44–1.30) 0.66 (0.37–1.19) 
No (n=28 334,  317 cases ) 1.33 (0.99–1.78) 1.43 (1.07–1.92) 
CI=confidence interval, OR=odds ratio. 
*
adjusted for baseline year and time interval between the survey waves. 
†
adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, 
and other lifestyle factors at baseline (except for the cluster variable).  
Total number of participant-observations and number of cases with unhealthy lifestyle at wave 3 in 
parentheses. 
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Table S7. Changes in body mass index, physical activity, and alcohol 
consumption from the baseline survey to the second survey wave among users 
of antihypertensive medications and statins versus non-initiators. 
Outcome 
Lifestyle factor 
Mean (SD*) Mean 
change 
β value (95% C) 
Unadjusted Adjusted 
/User group Baseline 2
nd
  survey (P value*) difference
† difference
‡
Antihypertensive medications 
Body mass index (kg/m
2
)
Initiators 
(n=7091) 
26.5 (4.30) 27.0 (4.54) 0.55 
(<.001) 
0.17 (0.13–0.21) 0.20 (0.17–0.24) 
Prevalent users 
(n= 22 576) 
27.1 (4.68) 27.4 (4.83) 0.33 
(<.001) 
-0.02 (-0.04–0.004) 0.08 (0.06–0.10) 
Non-initiators 
(n=48 197)  
24.9 (3.70) 25.3 (3.87) 0.36 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiator 
(n=7317) 
4.05 (3.67) 3.85 (3.53) -0.20
(<.001)
-0.15 (-0.23–[-0.08]) -0.14 (-0.22–[-0.06])
Prevalent users 
(n=23 496) 
3.76 (3.43) 3.66 (3.36) -0.10
(<.001)
-0.12 (-0.17–[-0.07]) -0.10 (-0.15–[-0.05])
Non-user 
(n=49 525) 
4.64 (3.98) 4.63 (4.00) -.01
(0.52)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=7366) 
69.9 (113) 66.7 (110) -3.13
(.004)
-2.73 (-4.58–[-0.88]) -2.17 (-4.07–[-0.26])
Prevalent users 
(n=23 666) 
66.1 (109) 63.7 (111) -2.47
(<.001)
-1.55 (-2.63 –[-0.47]) -0.95 (-2.13–0.22)
Non-initiators 
(n=49 723)   
61.4 (93.4) 60.9 (97.3) -0.52
(.16)
Reference Reference 
Statins 
Body mass index (kg/m
2
)
Initiators 
(n=5457) 
27.1 (4.45) 27.5 (4.63) 0.40 
(<.001) 
-0.01 (-0.05–0.04) 0.09 (0.05–0.14) 
Prevalent users 
(n=7373) 
27.6 (4.44) 27.6 (4.58) 0.18 
(<.001) 
-0.18 (-0.22–[-0.14]) 0.001 (-0.04–0.04) 
Non-initiators 
(n=65 034)  
25.4 (4.06) 25.8 (4.26) 0.40 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=5610) 
3.74 (3.47) 3.65 (3.35) -0.09
(.06)
-0.02 (-0.10–0.06) 0.04 (-0.04–0.12) 
Prevalent users 
(n=7673) 
3.60 (3.25) 3.56 (3.30) -0.03
(.41)
-0.03 (-0.09–0.03) 0.06 (-0.01–0.13) 
Non-initiators 
(n=67 055) 
4.46 (3.90) 4.41 (3.88) -0.05
(<.001)
Reference Reference 
Continued 
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Outcome 
Lifestyle factor 
Mean (SDa) Mean 
change 
β value (95% C) 
Unadjusted Adjusted 
/User group Baseline 2
nd
  survey (P value*) difference
† difference
‡
Alcohol consumption (grams/week) 
Initiators 
(n=5649) 
69.7 (106) 66.4 (111) -3.32
(.01)
-3.14 (-5.0–[-1.24]) -2.38 (-4.33–[-0.43])
Prevalent users 
(n=7710) 
68.4 (115) 65.3 (112) -3.13
(.01)
-1.30 (-3.08–[0.48]) 0.59 (-1.35–2.54) 
Non-initiators 
(n=67396)   
62.5 (97.9) 61.5 (99.4) -0.96
(.004)
Reference Reference 
CI=confidence interval; MET=metabolic equivalent of task; SD=standard deviation. 
*
SDs and P values reported here do not take into account that each participant may have contributed to more than
one dataset. 
† adjusted for baseline year and time interval between the survey waves.  
‡ 
adjusted for baseline year, time interval, age, sex, marital, occupational and employment status, diabetes, prevalent 
use of other therapeutic class, smoking status and other lifestyle factors at baseline. 
Table S8. Odds ratios for obesity, physical inactivity, high alcohol 
consumption, and current smoking at the second survey wave for users of 
antihypertensive medications and statins (versus non-initiators) stratified by 
presence of the respective unhealthy lifestyle at baseline. 
Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
 *
Adjusted
 † Unadjusted
 *
Adjusted
 † Ref. 
(wave 1) OR (95% CI) OR (95% CI) OR (95%CI) OR (95% CI) 
Antihypertensive medication 
Obesity 
Yes 1.27 (1.06–1.52) 1.28 (1.07–1.54) 1.37 (1.22–1.53) 1.38 (1.21–1.57) 1.00 
No 1.94 (1.73–2.17) 1.87 (1.67–2.10) 1.86 (1.69–1.99) 1.80 (1.65–1.96) 1.00 
Physical inactivity 
Yes 1.34 (1.22–1.48) 1.20 (1.09–1.33) 1.43 (1.35–1.52) 1.23 (1.15–1.31) 1.00 
No 1.36 (1.26–1.48) 1.14 (1.05–1.24) 1.48 (1.41–1.55) 1.18 (1.13–1.24) 1.00 
High alcohol consumption 
Yes 1.00 (0.87–1.15) 0.99 (0.85–1.14) 1.03 (0.94–1.12) 1.06 (0.96–1.17) 1.00 
No 1.05 (0.93 – 1.17) 1.04 (0.91–1.18) 1.04 (0.97–1.12) 1.13 (1.04–1.23) 1.00 
Current smoking 
Yes 0.76 (0.66–0.88) 0.76 (0.65–0.89) 0.98 (0.88–1.10) 0.96 (0.85–1.07) 1.00 
No 0.97 (0.76–1.24) 0.96 (0.75–1.24) 0.97 (0.85–1.10) 1.14 (0.98–1.32) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.26 (0.97–1.62) 1.28 (0.98–1.68) 1.35 (1.12–1.62) 1.39 (1.14–1.70) 1.00 
No 1.72 (1.43–2.07) 1.73 (1.43–2.10) 1.73 (1.53–1.96) 1.86 (1.63–2.13) 1.00 
Statins 
Obesity 
Yes 1.19 (0.98–1.44) 1.16 (0.96–1.40) 1.13 (0.98–1.32) 1.09 (0.92–1.29) 1.00 
No 1.48 (1.30–1.67) 1.38 (1.21–1.57) 1.46 (1.30–1.64) 1.28 (1.13–1.45) 1.00 
Physical inactivity 
Yes 1.27 (1.15–1.41) 1.10 (0.99–1.22) 1.32 (1.20–1.45) 1.04 (0.94–1.15)  1.00 
No 1.34 (1.23–1.45) 1.04 (0.96–1.14) 1.39 (1.30–1.49) 1.02 (0.95–1.11)  1.00 
High alcohol consumption 
Yes 0.96 (0.83–1.12) 0.93 (0.80–1.08) 0.98 (0.86–1.12) 0.92 (0.80–1.06) 1.00 
No 0.92 (0.81–1.04) 0.95 (0.84–1.09) 0.88 (0.79–1.00) 0.99 (0.87–1.13) 1.00 
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Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
 *
Adjusted
 b
Unadjusted
 *
Adjusted
 † Ref. 
(wave 1) OR (95% CI) OR (95% CI) OR (95%CI) OR (95% CI) 
Current smoking 
Yes 0.65 (0.55–0.77) 0.63 (0.53–0.75) 1.08 (0.91–1.28) 1.08 (0.90–1.31)  1.00 
No 0.92 (0.71–1.19) 1.01 (0.77–1.32) 0.65 (0.52–0.82) 0.87 (0.66–1.11) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.04 (0.78–1.37) 1.00 (0.75–1.33) 1.29 (1.00–1.66) 1.13 (0.84–1.50) 1.00 
No 1.28 (1.05–1.56) 1.13 (0.92–1.39) 1.38 (1.16–1.63) 1.22 (0.99–1.50) 1.00 
OR=odds ratio; CI=confidence interval. 
*
adjusted for baseline year and time interval between the surveys waves.
† adjusted for baseline year and time interval, age, sex, marital, occupational, and employment status, 
prevalent use of other therapeutic class, diabetes, and other lifestyle factors (except for the cluster 
variable) at baseline. 
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Table S9. Baseline characteristics of the 81 772 participant-observations 
stratified by use of antihypertensive medications and statins. 
Characteristics Antihypertensive medication Statins 
at baseline 
(wave 1) 
Initiators 
(n=7472) 
Prevalent 
users 
(n=23 992) 
Non-
initiators 
(n=50 308) 
Initiators 
(n=5736) 
Prevalent 
users 
(n=7829) 
Non- 
initiators 
(n=68 207) 
Baseline year 
2000/02 
2004/05 
2008/09 
Age, mean  
(SD), years 
1947 (26.1) 
3129 (41.9) 
2396 (32.1) 
52.3 (6.72) 
4571 (19.1) 
7552 (31.5) 
11 869(49.5) 
54.8 (7.22) 
14559 (28.9) 
16592 (33.0) 
19157 (38.1) 
50.9 (6.97) 
1431(25.0) 
2431 (42.4) 
1874 (32.7) 
54.8 (6.30) 
771(0.9) 
2258 (28.8) 
4800 (61.3) 
58.3 (6.76) 
18875 (27.7) 
22584 (33.1) 
26748 (39.2) 
51.3 (6.96) 
40–49 2950 (39.5) 6433 (26.8) 24694 (49.1)   1326 (23.1) 958 (12.2) 31793 (46.6) 
50–59 3511 (47.0) 11663 (48.6) 20028 (39.8) 3235 (56.4) 3581 (45.7) 28386 (41.6) 
60–78 1011 (13.5) 5896 (24.6) 5586 (11.1) 1175 (20.5) 3290 (42.0) 8028 (11.8)   
Women 6197 (82.9) 20315 (84.7) 42104 (83.8) 4527 (78.9) 6101 (77.9) 57988 (85.0) 
Married  5623 (76.2) 17870 (75.4) 38172 (76.7) 4346 (76.8) 5886 (76.2) 51433 (75.4) 
Occupational status 
Upper-grade non-
manual workers 
2165 (29.3) 7232 (30.5) 16 561(33.2) 1710 (30.2) 2423 (31.4) 21825 (32.3) 
Lower-grade non-
manual workers 
1979 (27.8) 6157 (26.0) 13 295(26.7) 1303 (23.0)  1673 (21.7) 18455 (27.3) 
Clerks 529 (7.2) 1997 (8.4) 3448 (6.9) 455 (8.0) 612 (7.92) 4907 (7.3) 
Manual workers 2720 (36.8) 8325 (35.1) 16535 (33.2)  2203 (38.9) 3016 (39.1) 22361 (33.1) 
Employed 6858 (91.9)   19581 (81.8) 46549 (92.6)   5042 (88.0) 5287 (67.8) 62659 (92.0) 
Body weight 
Normal 2999 (41.2) 8543 (36.6) 28199 (57.2)   1991 (35.5)  2378 (31.1)  35372 (53.1) 
Overweight 2863 (39.3)  9181 (39.4)  16342 (33.2)   2369 (42.2) 3394 (44.4) 22623 (34.0) 
Obese 1416 (19.5)   5600 (24.0) 4746 (9.63)  1249 (22.3)  1867 (24.4) 8646 (13.0) 
Physical activity 
Active 2762 (37.3) 8105 (34.2) 22172 (44.5) 1928 (34.0)  2530 (32.7) 28581 (42.3) 
Moderate 2502 (33.8)   8222 (34.6)  16514 (33.1)   1918 (33.8)  2658 (34.3) 22662 (33.5) 
Inactive 2134 (28.9) 7406 (31.2) 11171 (22.4)   1831 (32.3) 2559 (33.0) 16321 (24.2) 
  Alcohol consumption 
Moderate 5256 (70.9) 16522 (69.4) 36482 (73.0) 3996 (70.2)  5333 (68.7) 48931 (72.2) 
None 1042 (14.1) 3925 (16.5) 7140 (14.3) 843 (14.8)  1369 (17.6) 9895 (14.6) 
High 1118 (15.1) 3376 (14.2) 6376 (12.8)  852 (15.0)  1065 (13.7)  8953 (13.2) 
Smoking 
Never 4711 (64.8)   16 047(68.6)  33607 (68.6)  3655 (65.7)  5319 (69.4) 45391 (68.3) 
Former 1458 (20.1)   4572 (19.5) 8578 (17.5)  1107 (19.9)  1466 (19.1) 12035 (18.1) 
Current 1099 (15.1)   2780 (11.9) 6823 (13.9)  798 (14.4)  875 (11.4) 9029 (13.6) 
Number of unhealthy lifestyles* 
0 3414 (45.8)   10707 (44.8)   28299 (56.3)   2489 (43.5) 3446 (44.2) 36485 (53.6) 
1–2 3746 (50.3) 12245 (51.2)   20925 (41.7) 2990 (52.2) 4023 (51.6)  29903 (43.9)  
3–4 293 (3.9) 969 (4.1)   1013 (2.0)  245 (4.3) 327 (4.2)  1703 (2.5) 
History of 
antihypertensive 
medication use 
 NA 23 992 (100)  NA 2514 (43.8)  4907 (62.7)  16571 (24.3)  
History of statin 
use 
566 (7.6)  4907 (20.5) 2356 (4.7) NA 7829 (100.0)  NA 
Diabetes 203 (2.7)  1602 (6.7) 428 (0.9)  330 (5.8) 1090 (13.9)  813 (1.2)  
Numbers are No. (%) unless otherwise specified.  NA=not applicable; SD=standard deviation. 
*obesity, physical inactivity, high alcohol consumption, and current smoking.
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Table S10. Changes in body mass index, alcohol consumption, and physical 
activity from baseline survey to the second survey wave among users of 
preventive medication versus non-initiators, by baseline year.  
Outcome 
Lifestyle factor 
Mean (SD) Mean (SD) Mean 
change 
β value (95% CI) 
Unadjusted  Adjusted 
/User group Baseline 2
nd
  survey (P value) difference
*
difference
†
Baseline in 2000/02 
Body mass index (kg/m2) 
Initiators 
(n=2318) 
26.2 (4.12) 26.8 (4.37) 0.56 
(<.001) 
0.17 (0.11–0.25) 0.21 (0.14–0.29) 
Prevalent users 
(n=4699) 
26.7 (4.42) 27.1 (4.62) 0.44 
(<.001) 
0.06 (0.004–0.11) 0.12 (0.06–0.18) 
Non-initiators 
(n=13 256)  
24.7 (3.58) 25.1 (3.72) 0.38 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=2352) 
4.09 (3.70)  3.88 (3.44) -0.21
(.01)
-0.30 (-0.47–[-0.13]) -0.27 (-0.49–[-0.09])
Prevalent users 
(n=4827) 
3.73 (3.43)  3.72 (3.36) -0.01
(0.80)
-0.10 (-0.23–0.04) -0.06 (-0.17–0.08)
Non-initiators 
(n=13 491) 
4.58 (4.00)  4.64 (4.03) 0.06
(.07)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=2376) 
67.3 (101) 69.3 (108) 2.01 
(0.28) 
-2.11 (-5.88–1.66) -1.61 (-5.48–2.26)
Prevalent users 
(n=4883) 
64.8 (103) 69.6 (117) 4.77 
(.003) 
0.16 (-2.65–2.98) 0.63 (-2.38–3.63) 
Non-initiators 
(n=13 574)   
60.1 (88.4) 63.8 (98.2) 3.72 
(<.001) 
Reference Reference 
Baseline in 2004/05 
Body mass index (kg/m2) 
Initiators 
(n=3541) 
26.3 (4.16) 26.9 (4.46) 0.61 
(<.001) 
0.16 (0.10–0.23) 0.24 (0.17–0.31) 
Prevalent users 
(n=8048) 
27.0 (4.54) 27.4 (4.74) 0.40 
(<.001) 
-0.03 (-0.08–0.02) 0.13 (0.08–0.18) 
Non-initiators 
(n=14 485)  
24.8 (3.64) 25.3 (3.84) 0.45 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=3623) 
4.16 (3.71) 3.81 (3.93) -0.35
(<.001)
0.04 (-0.10–0.18) 0.04 (-0.10–0.19) 
Prevalent users 
(n=8299) 
3.88 (3.43) 3.52 (3.24) -0.37
(<.001)
0.02 (-0.08–0.13) 0.02 (-0.09–0.14) 
Non-initiators 
(n=14 852) 
4.85 (4.00) 4.47 (3.84) -0.38
(<.001)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=3651) 
69.3 (110) 64.9 (107) -4.40
(.01)
-3.53 (-6.80–[-0.26]) -2.76 (-6.11–0.59)
Prevalent users 
(n=8353) 
68.0 (107) 65.3 (112) -2.61
(.01)
-1.38 (-3.81–1.04) 0.17 (-2.47–2.78) 
Non-initiators 
(n=14 915)   
63.4 (98.8) 61.7 (95.3) -1.66
(.02)
Reference Reference 
Continued 
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Outcome 
Lifestyle factor 
Mean (SD) Mean (SD) Mean 
change 
β value (95% CI) 
Unadjusted Adjusted 
/User group Baseline 2
nd
  survey (P value) difference
*
difference
†
Baseline in 2008/09 
Body mass index (kg/m2) 
Initiators 
(n=2566) 
26.4 (4.31) 26.8 (4.51) 0.37 
(<.001) 
0.06 (-0.02–0.14) 0.11 (0.04–0.19) 
Prevalent users 
(n=12 601) 
27.2 (4.69) 27.4 (4.80) 0.22 
(<.001) 
-0.08 (-0.13–[-0.04]) 0.04 (-0.01–0.09) 
Non-initiators 
(n=16 350)  
25.0 (3.82) 25.3 (3.99) 0.30 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=2683) 
4.05 (3.80) 4.16 (4.31) 0.11 
(.13) 
-0.15 (-0.31–0.002) -0.13 (-0.29–0.03)
Prevalent users 
(n=13 242) 
3.73 (3.42) 3.78 (3.48) 0.06 
(.06) 
-0.21 (-0.30–[-0.13]) -0.17 (-0.27–[-0.07])
Non-initiators 
(n=16 969) 
4.64 (3.86) 4.89 (4.16) 0.24 
(<.001) 
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=2694) 
69.4 (116) 64.6 (113) -4.80
(.01)
-2.04 (-5.71–1.64) -1.48 (-5.24–2.27)
Prevalent users 
(n=13 309) 
65.4 (111) 60.6 (109) -4.86
(.040)
-2.80 (-4.86–[-0.75]) -2.04 (-4.30–0.21)
Non-initiators 
(n=16 999)   
59.9 (92.0) 57.2 (93.7) -2.68
(<.001)
Reference Reference 
 CI=confidence interval, MET=metabolic equivalent of task, SD=standard deviation. 
*
adjusted for time interval between the survey waves.
† adjusted for time interval, age, sex, marital, occupational, and employment status, diabetes, smoking 
status and other lifestyle factors at baseline.  
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Table S11. Odds ratios for obesity, physical inactivity, high alcohol consumption 
and current smoking at the second survey wave for users of preventive 
medication (versus non-initiators) stratified by presence of the respective 
unhealthy lifestyle at baseline, by baseline year.  
Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
*
Adjusted
† Unadjusted
*
Adjusted
†
(wave 1) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Ref. 
Baseline in 2000/02 
Obesity 
Yes 1.71 (1.20–2.42) 1.62 (1.13–2.31) 1.74 (1.35–2.24) 1.57 (1.21–2.05) 1.00 
No 1.96 (1.59–2.41) 1.97 (1.59–2.43) 1.99 (1.69–2.34) 2.05 (1.73–2.43) 1.00 
Physical inactivity 
Yes 1.37 (1.15–1.64) 1.24 (1.03–1.50) 1.41 (1.24–1.61) 1.25 (1.09–1.44) 1.00 
No  1.27 (1.11–1.46) 1.06 (0.92–1.23) 1.45 (1.31–1.61) 1.20 (1.07–1.34) 1.00 
High alcohol consumption 
Yes 1.17 (0.91–1.51) 1.12 (0.86–1.46) 1.06 (0.87–1.28) 0.98 (0.79–1.20) 1.00 
No  1.07 (0.89–1.30) 1.13 (0.93–1.37) 1.12 (0.97–1.29) 1.23 (1.06–1.43) 1.00 
Current smoking 
Yes 0.60 (0.46–0.78) 0.59 (0.45–0.78) 0.81 (0.64–1.03) 0.80 (0.62–1.02) 1.00 
No 0.46 (0.28–0.75) 0.49 (0.29–0.82) 0.78 (0.58–1.04) 0.95 (0.69–1.30) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.36 (0.84–2.21) 1.41 (0.86–2.31) 1.54 (1.05–1.90) 1.44 (0.96–2.16) 1.00 
No 1.60 (1.16–2.20) 1.67 (1.21–2.32) 1.64 (1.28–2.10) 1.81 (1.40–2.35) 1.00 
Baseline in 2004/05 
Obesity 
Yes 1.25 (0.94–1.66) 1.33 (1.00–1.77) 1.39 (1.13–2.24) 1.56 (1.25–1.96) 1.00 
No 1.80 (1.53–2.12) 1.78 (1.51–2.10) 1.73 (1.52–1.97) 1.77 (1.55–2.03) 1.00 
Physical inactivity 
Yes 1.13 (0.98–1.31)   1.01 (0.87–1.18) 1.44 (1.29–1.61) 1.20 (1.06–1.35) 1.00 
No  1.37 (1.23–1.53) 1.17 (1.04–1.30) 1.49 (1.38–1.62) 1.19 (1.09–1.30) 1.00 
High alcohol consumption 
Yes  0.88 (0.72–1.06) 0.91 (0.74–1.11) 1.07 (0.92–1.24) 1.15 (0.98–1.36) 1.00 
No  1.03 (0.87–1.21) 1.09 (0.92–1.30) 0.92 (0.81–1.05) 1.10 (0.96–1.26) 1.00 
Current smoking 
Yes 0.78 (0.63–0.96) 0.74 (0.59–0.93) 0.92 (0.78–1.10) 0.90 (0.75–1.09) 1.00 
No 1.13 (0.82–1.58) 1.21 (0.86–1.71) 0.96 (0.74–1.24) 1.18 (0.89–1.56) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.24 (0.81–1.89) 1.16 (0.75–1.79) 1.42 (1.03–1.97) 1.29 (0.90–1.83) 1.00 
No 1.45 (1.11–1.94) 1.53 (1.15–2.03) 1.71 (1.39–2.10) 1.88 (1.51–2.34) 1.00 
Baseline in 2008/09 
Obesity 
Yes 1.24 (0.93–1.65) 1.25 (0.93–1.68) 1.22 (1.04–1.44) 1.25 (1.05–1.50) 1.00 
No 1.76 (1.45–2.14) 1.76 (1.44–2.14) 1.76 (1.56–1.98) 1.83 (1.61–2.43) 1.00 
Physical inactivity 
Yes 1.40 (1.20–1.64) 1.28 (1.09–1.51) 1.46 (1.34–1.60) 1.22 (1.10–1.35) 1.00 
No  1.26 (1.11–1.44) 1.03 (0.90–1.18) 1.52 (1.41–1.63) 1.16  (1.07–1.25) 1.00 
High alcohol consumption 
Yes 1.10 (0.88–1.37) 1.11 (0.89–1.39) 0.97 (0.85–1.09) 0.97 (0.85–1.12) 1.00 
No  0.97 (0.79–1.18) 1.00 (0.81–1.22) 1.07 (0.96–1.19) 1.19 (1.06–1.34) 1.00 
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Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
*
Adjusted
† Unadjusted
*
Adjusted
†
(wave 1) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) Ref. 
Current smoking 
Yes 0.86 (0.65–1.07) 0.86 (0.66–1.12) 1.03 (0.88–1.22) 1.07 (0.89–1.27) 1.00 
No 1.14 (0.96–1.86) 1.35 (1.00–1.82) 0.95 (0.79–1.14) 1.15 (0.77–1.41) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.15 (0.72–1.82) 1.21 (0.75–1.95) 1.31 (0.99–1.73) 1.37 (1.01–1.85) 1.00 
No 1.98 (1.46–2.69) 1.99 (1.46–2.71) 1.89 (1.56–2.29) 2.14 (1.73–2.64) 1.00 
CI=confidence interval, OR=odds ratio. 
*
adjusted for baseline year and time interval between the survey waves.
† adjusted for baseline year, time interval, age, sex, marital, occupational, and employment status, 
diabetes, and other lifestyle factors at baseline (except for the cluster variable). 
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Table S12. Changes in body mass index, physical activity, and alcohol 
consumption from the baseline survey to the 2nd survey wave among users of 
preventive medication (versus non-initiators), by sex.
Outcome 
Lifestyle 
factor 
Mean (SD
*
) Mean 
change 
β value (95% C) 
Unadjusted   Adjusted 
/User group Baseline 2
nd
  survey (P value
*
) difference
† difference
‡
Women 
Body mass index (kg/m2) 
Initiators 
(n=6919) 
26.2 (4.29) 26.7 (4.55) 0.57 
(<.001) 
0.14 (0.11–0.18) 0.20 (0.16–0.23) 
Prevalent users 
(n=21,154) 
26.9 (4.68) 27.2 (4.81) 0.34 
(<.001) 
-0.05 (-0.08–[-0.03]) 0.07 (0.04–0.10) 
Non-initiators 
(n=37 063)  
24.7 (3.74) 25.1 (3.92) 0.40 
(<.001) 
Reference Reference 
  Physical activity (MET-hours/day) 
Initiators 
(n=7142) 
4.04 (3.61) 3.88 (3.49) -0.17
(<.001)
0.001 (-0.07–0.07) -0.11 (-0.19–[-0.04])
Prevalent users 
(n=22,082) 
3.75 (3.34) 3.66 (3.30) -0.09
(.003)
-0.12 (-0.17–[-0.08]) -0.09 (-0.13–[-0.04])
Non-initiators 
(n=38 157) 
4.60 (3.86) 4.60 (3.89) 0.003
(.87)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=7200) 
52.9 (87.5) 50.6 (82.3) -2.27
(.02)
-2.42 (-4.98–[-0.86]) -1.76 (-3.40–[-0.12])
Prevalent users 
(n=22,231) 
50.9 (86.5) 48.7 (86.7) -2.26
(<.001)
-1.52 (-2.54–[-0.50]) -0.95 (-2.08–0.18)
Non-initiators 
(n=38 327)   
49.5 (77.8) 49.2 (80.8) -0.29
(0.44)
Reference Reference 
Men 
Body mass index (kg/m2) 
Initiators 
(n=1506) 
26.9 (3.67) 27.3 (3.95) 0.32 
(<.001) 
0.09 (0.02–0.18) 0.15 (0.07–0.23) 
Prevalent users 
(n=4194) 
27.7 (4.11) 28.0 (4.37) 0.22 
(<.001) 
0.05 (-0.01–0.11)  0.14 (0.09–0.20) 
Non-initiators 
(n=7028)  
25.7 (3.33) 25.9 (3.45) 0.21 
(<.001) 
Reference Reference 
Physical activity (MET-hours/day) 
Initiators 
(n=1516) 
 4.41 (4.26) 4.25 (4.01) -0.16
(.14)
0.001 (-0.19–0.19) 0.01 (-0.19–0.20) 
Prevalent users 
(n=4286) 
 3.91 (3.86) 3.80 (3.80) -0.11
(.06)
-0.05 (-0.17–0.06) -0.07 (-0.20–0.07)
Non-initiators 
(n=7155) 
 5.19 (4.72) 5.09 (4.65) -0.10
(.05)
Reference Reference 
Alcohol consumption (grams/week) 
Initiators 
(n=1521) 
144 (161) 139 (166) -5.17
(.16)
-3.17 (-9.15–2.82) -2.05 (-8.29–4.19)
Prevalent users 
(n=4315) 
144 (162) 141 (174) -3.01
(.18)
-1.37 (-5.28–2.55) 0.24 (-4.09–4.58) 
Non-initiators 
(n=7161)   
123 (135) 122 (137) 1.12
(.37)
Reference Reference 
CI=confidence interval; MET=metabolic equivalent of task; SD=standard deviation. 
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*
SDs and P values reported here do not take into account that each participant may have contributed to
more than one dataset. 
†
adjusted for baseline year and time interval between the survey waves. 
‡
adjusted for baseline year, time
interval, age, sex, marital, occupational, and employment status, diabetes, smoking status and other 
lifestyle factors at baseline.   
Table S13. Odds ratios for obesity, physical inactivity, high alcohol consumption 
and current smoking at the second survey wave for users of preventive 
medication (versus non-initiators) stratified by presence of the respective 
unhealthy lifestyle at baseline, by sex.
Initiators Prevalent users Non-
initiators 
Baseline Unadjusted
*
Adjusted
† Unadjusted
*
Adjusted
†
(wave 1) OR (95% CI) OR (95% CI) OR (95%CI) OR (95% CI) Reference 
Women 
Obesity 
Yes 1.34  (1.08–1.68) 1.41 (1.15–1.73) 1.30 (1.15–1.47) 1.33 (1.16–1.53) 1.00 
No 1.78 (1.51–2.13) 1.84 (1.62–2.08) 1.79 (1.64–1.95) 1.82 (1.66–1.99) 1.00 
Physical inactivity 
Yes 1.32 (1.19–1.46) 1.20 (1.08–1.32) 1.43 (1.33–1.53) 1.21 (1.13–1.30) 1.00 
No 1.33 (1.11–1.55) 1.10 (1.00–1.22) 1.49 (1.41–1.57) 1.17 (1.10–1.24) 1.00 
High alcohol consumption 
Yes 1.01 (0.87–1.17) 1.01 (0.86–1.19) 1.05 (0.94–1.17) 1.04  (0.93–1.16) 1.00 
No 0.97 (0.87–1.09)   1.04 (0.93–1.18) 0.99 (0.92–1.07) 1.17 (1.07–1.27) 1.00 
Current smoking 
Yes 0.75 (0.64–0.89) 0.75 (0.63–0.89) 0.93 (0.83–1.06) 0.93 (0.81–1.06) 1.00 
No 0.98 (0.78–1.24)   1.01 (0.79–1.29) 0.93 (0.80–1.08) 1.16 (0.98–1.37) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.15 (0.83–1.61)  1.17 (0.83–1.64) 1.27 (1.02–1.58) 1.24 (0.97–1.60) 1.00 
No 1.65 (1.34–2.03) 1.75 (1.40–2.17) 1.74 (1.51–2.01) 2.01 (1.73–2.33) 1.00 
Men 
Obesity 
Yes 1.21 (0.83–1.76) 1.20 (0.80–1.91) 1.82 (1.67–1.98) 1.70 (1.24–2.33) 1.00 
No 1.78 (1.20–2.64) 1.76 (1.36–2.29) 1.80 (1.49–2.19) 1.78 (1.44–2.20) 1.00 
Physical inactivity 
Yes 1.13 (0.90–1.40) 1.01 (0.81–1.26) 1.49 (1.28–1.74) 1.24 (1.04–1.46) 1.00 
No 1.29  (1.10–1.53) 1.09 (0.91–1.30) 1.53 (1.35–1.74) 1.23 (1.08–1.40) 1.00 
High alcohol consumption 
Yes 1.02 (0.81–1.28) 1.03 (0.81–1.31) 0.95 (0.81–1.12) 1.00 (0.84–1.20) 1.00 
No 1.17 (0.95–1.44)  1.13 (0.90–1.42) 1.17 (1.02–1.34) 1.16 (0.98–1.36) 1.00 
Current smoking 
Yes 0.70 (0.52–0.94) 0.68 (0.51–0.90) 0.99 (0.78–1.25) 0.94 (0.72–1.21) 1.00 
No 1.13 (0.75–1.69) 1.15 (0.76–1.74) 0.80 (0.57–1.10) 0.96 (0.69–1.34) 1.00 
Cluster of 3–4 unhealthy lifestyles 
Yes 1.45 (0.91–2.31)  1.57 (0.95–2.60) 1.75 (1.24–2.46) 1.81 (1.23–2.65) 1.00 
No 1.48 (1.07–2.06) 1.58 (1.13–2.21) 1.92 (1.56–2.36) 1.93 (1.52–2.44) 1.00 
OR=odds ratio; CI=confidence interval. 
*
adjusted for baseline year and time interval between the survey waves.
†
adjusted for baseline year and time interval, age, marital, occupational, and employment status, 
diabetes, and other lifestyle factors (except for the cluster variable) 
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